Aldeyra announces positive results from Phase 2b clinical trial
Date: 2018-10-01   Author: Paroma Bhattacharya  Category: #technology

Aldeyra announces positive results from Phase 2b clinical trial

Aldeyra Therapeutics, Inc., a biotechnology company engaged in research and development of medicines related to immune-mediated diseases, has recently announced to have received positive results from its topical ocular reproxalap’s Phase 2b clinical trial, conducted on patients with dry eye disease.

As per an official press release, John Sheppard, M.D., Professor of Ophthalmology at Eastern Virginia Medical School, said that the recently announced positive results confirm the potential of reproxalap, a drug with a novel mechanism of action, as a promising therapeutic agent for treating dry eye disease, which remains a persistently challenging medical condition for many patients worldwide.

Sources suggest that the randomized, parallel-group, vehicle-controlled, double-masked, multi-center, Phase 2b clinical trial investigated 0.1% and 0.25% reproxalap concentrations activity relative to vehicle, along with observed clear dose response. Despite being consistent with prior clinical trials, topical ocular reproxalap was well tolerated, while adverse events were speculated to be generally mild.

Nearly three hundred patients suffering from dry eye disease were equally treated with 0.1%, 0.25%, or vehicle dosages for 12 weeks. The primary objective of the trial was to evaluate the safety and efficiency of reproxalap for the treatment of the symptoms and signs of dry eye disease, in order to confirm endpoint selection, to select appropriate drug concentration, and to determine sample size for a pivotal Phase 3 clinical program.

Todd C. Brady, CEO of Aldeyra, was quoted saying that with the successful Phase 2b results the company is looking forward to initiating a Phase 3 program in dry eye disease in 2019, soon after following discussion with regulatory authorities.

The addition of treatment of dry eye disease to Aldeyra’s clinical portfolio, including Phase 3 clinical trials in noninfectious anterior uveitis and allergic conjunctivitis, will highlight the potential of reproxalap as a novel ophthalmic therapy, said Brady.



About Author


Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from...

Read More

More from Paroma


Post Recommendents

Cooling Tower Rental Market Research Report Analysis and Forecasts to 2025
Author: Partha Ray

The latest report about ' Cooling Tower Rental market' Added by Market Study Report, LLC, features recent and future growth trends related to the business besides information on the myriad regions that belong to the geographical spectrum o...


Brand Counterfeiting Grail Market, Share, Growth, Trends and Forecast to 2025: Market Study Report
Author: Partha Ray

Advanced report on ' Brand Counterfeiting Grail market' Added by Market Study Report, LLC, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscap...


Hadoop-as-a-Service (HaaS) Market by Type, Application, Element - Global Trends and Forecast to 2025
Author: Partha Ray

The latest report on ' Hadoop-as-a-Service (HaaS) market' as Added by Market Study Report, LLC, offers comprehensive details on industry size, regional spectrum and revenue estimates of the business. In addition, the report stresses on maj...